• 1
    Sjoberg J, Halthur C, Kristinsson SY, et al. Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood. 2012;119:990-996.
  • 2
    Favier O, Heutte N, Stamatoullas-Bastard A, et al; European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer. 2009;115:1680-1691.
  • 3
    Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol. 2002;20:2101-2108.
  • 4
    Schonfeld SJ, Gilbert ES, Dores GM, et al. Acute myeloid leukemia following Hodgkin lymphoma: a population-based study of 35,511 patients. J Natl Cancer Inst. 2006;98:215-218.
  • 5
    Hodgson DC, Gilbert ES, Dores GM, et al. Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol. 2007;25:1489-1497.
  • 6
    Dores GM, Metayer C, Curtis RE, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol. 2002;20:3484-3494.
  • 7
    Bhatia S, Yasui Y, Robison LL, et al; Late Effects Study Group. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386-4394.
  • 8
    Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol. 2011;29:4096-4104.
  • 9
    Milano MT, Li H, Constine LS, Travis LB. Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients. Cancer. 2011;117:5538-5547.
  • 10
    Milano MT, Li H, Gail MH, Constine LS, Travis LB. Long-term survival among patients with Hodgkin's lymphoma who developed breast cancer: a population-based study. J Clin Oncol. 2010;28:5088-5096.
  • 11
    National Cancer Institute. SEER Training Modules. Accessed April 17, 2013.
  • 12
    Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
  • 13
    R Foundation. R: A Language and Environment for Statistical Computing. Version 2.13.2. Vienna, Austria: R Project for Statistical Computing; 2011.
  • 14
    Gray RJ. cmprsk: Subdistribution Analysis of Competing Risks. R Package Version 2.2-2. Vienna, Austria: R Project for Statistical Computing; 2011.
  • 15
    Ripatti S, Palmgren J. Estimation of multivariate frailty models using penalized partial likelihood. Biometrics. 2000;56:1016-1022.
  • 16
    Themeau T. A Package for Survival Analysis in S. R Package Version 2.36-12. Vienna, Austria: R Project for Statistical Computing; 2012.
  • 17
    Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov. 2011 Sub, Vintage 2009 Populations (2000-2009) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total US, 1969-2010 Counties. Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Science, Surveillance Research Program, Surveillance Systems Branch; 2012, based on the November 2011 submission.
  • 18
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.
  • 19
    Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:1569-1580.
  • 20
    Persky DO, Unger JM, Spier CM, et al; Southwest Oncology Group. Phase II study of rituximab plus 3 cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol. 2008;26:2258-2263.
  • 21
    Vellenga E, van Putten WL, van't Veer MB, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood. 2008;111:537-543.
  • 22
    Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23:4430-4438.
  • 23
    Mounier N, Spina M, Gabarre J, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood. 2006;107:3832-3840.
  • 24
    Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22:1454-1459.
  • 25
    Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27:1202-1208.
  • 26
    Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009;27:4555-4562.